Faron receives grant from Business Finland
Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron receives €800,000 grant from Business Finland as part of Cancer IO, Finland's leading Personalized Health Program - Grant will enable state-of-the-art characterization of immunological responses in MATINS trial- Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members Company announcement, 11 May 2020 at 12.00 PM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical